Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110631 | 0.88 | ALDH1A1 (0.35) | RORCNPY1R | |
| SCHEMBL7112812 | 0.84 | HDAC3 (0.33) | RORCMMP1MMP2MMP3MMP9 | |
| SCHEMBL7110961 | 0.84 | HDAC3 (0.33) | RORCMMP1MMP2MMP3MMP9 | |
| SCHEMBL7109313 | 0.75 | ALDH1A1 (0.38) | RORCNPY1R | |
| SCHEMBL7110629 | 0.70 | ALDH1A1 (0.40) | RORC | |
| SCHEMBL7109309 | 0.68 | KDM1A (0.38) | RORC | |
| SCHEMBL6255710 | 0.64 | LMNA (0.37) | NPY1R | |
| SCHEMBL7569169 | 0.59 | RAB9A (0.38) | — | |
| SCHEMBL6255689 | 0.59 | GABRA1 (0.44) | — | |
| SCHEMBL6255685 | 0.59 | GABRA1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299103-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | Aventis Pharma S.A. (FR) | 2003-04-09 | — | — | EP | disclosed |
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2001093867-A1 | 4,5-DIHYDRO-THIAZO-2-YLAMINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019427-A1 | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof | ALK, QDPR, CYP3A7 | RORC 1021/4885MMP1 3608/4885MMP2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.